Globulins Patents (Class 530/386)
  • Publication number: 20150038420
    Abstract: The present invention relates to methods for treating or preventing a properd related disease or disorder in a subject in need thereof, or for reducing mortality of a subject suffering from a properdin-related disease or disorder, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a properdin protein. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
    Type: Application
    Filed: August 31, 2012
    Publication date: February 5, 2015
    Applicant: THE MEDICINES COMPANY
    Inventors: Hans-Wilhelm Schwaeble, Mohammed Youssif Ibrahim Ali, Dimitrios Gkountis
  • Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Publication number: 20150031618
    Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of ?1m.
    Type: Application
    Filed: January 31, 2013
    Publication date: January 29, 2015
    Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
  • Publication number: 20150005183
    Abstract: This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells histologicaly defined as early stage (stage 0) breast cancer and primary breast cancer cells histologicaly defined as late stage (stage 3) breast cancer. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the that a breast cancer patient's cancer is in an early, non-aggressive stage or in a late, aggressive stage. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the aggressiveness of late stage breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 1, 2015
    Applicant: EXPRESSION PATHOLOGY, INC.
    Inventors: David Krizman, Marlene M. Darfler, Thomas P. Conrads, Brian L. Hood
  • Publication number: 20140323324
    Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 30, 2014
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara
  • Publication number: 20140227717
    Abstract: Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.
    Type: Application
    Filed: February 10, 2014
    Publication date: August 14, 2014
    Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
  • Publication number: 20140206020
    Abstract: Methods, compositions and kits are disclosed directed at voriconazole derivatives, immunogens, signal generating moieties, antibodies that bind voriconazole and immunoassays for detection of voriconazole.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 24, 2014
    Inventors: Johnny Valdez, SOON J. OH, BYUNG SOOK MOON
  • Patent number: 8759281
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: June 24, 2014
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 8759493
    Abstract: A new gene —MN— and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: June 24, 2014
    Assignee: Institute of Virology Slovak Academy of Sciences
    Inventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
  • Patent number: 8741629
    Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: June 3, 2014
    Assignee: Heliae Development, LLC
    Inventor: Aniket Kale
  • Publication number: 20140134201
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 15, 2014
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • Patent number: 8703143
    Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: April 22, 2014
    Assignee: Philogen S.p.A.
    Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
  • Patent number: 8703920
    Abstract: The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: April 22, 2014
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Eric Lepin, Anna M. Wu
  • Patent number: 8686225
    Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: April 1, 2014
    Assignee: Ventria Bioscience Inc.
    Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
  • Patent number: 8642531
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: February 4, 2014
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Publication number: 20130323751
    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.
    Type: Application
    Filed: January 20, 2012
    Publication date: December 5, 2013
    Applicant: University of Pittsburgh - of the Common-Wealth System of Higher Education
    Inventors: Kai Singbartl, John A. Kellum, JR.
  • Patent number: 8580929
    Abstract: The present invention concerns a novel retinoic acid regulated gene whose expression product displays useful morphogenic/mitogenic properties. The present invention further concerns an isolated nucleic acid of SEQ ID NO:1 encoding a retinoic acid regulated expression product having an amino acid sequence of SEQ ID NO:2.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: November 12, 2013
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Nancy Y. Ip, William M. W. Cheung
  • Patent number: 8546546
    Abstract: An antibody that binds to Mucin17 (Muc17) is disclosed. The antibody of the present invention preferably binds to the peptide of SEQ ID NO:3 and does not bind to the peptide of SEQ ID NO:4 or the peptide of SEQ ID NO:5. Also disclosed are an anti-cancer agent, preferably an anti-cancer agent for pancreatic cancer, which comprises the antibody of the present invention, as well as a method of diagnosing cancer using the antibody of the present invention, preferably the antibody of the present invention that does not bind to the secreted-form of Muc17.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: October 1, 2013
    Assignee: Forerunner Pharma Research Co., Ltd.
    Inventor: Kiyotaka Nakano
  • Patent number: 8512712
    Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: August 20, 2013
    Assignee: Oncolytics Biotech Inc.
    Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
  • Publication number: 20130203076
    Abstract: Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine at the 3-position of one of the phenyl rings. Antibodies produced from immunogenic EDDP conjugates and labeled EDDP conjugates are employed in assays for determining the presence and/or amount of EDDP in samples suspected of containing EDDP.
    Type: Application
    Filed: February 2, 2012
    Publication date: August 8, 2013
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventor: Bhalchandra Lele
  • Patent number: 8492613
    Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: July 23, 2013
    Assignee: Stichting Dienst Landbouwkundig Onderzoek
    Inventors: Hendrikus Antonius Cornelis Bakker, Dionisius Elisabeth Antonius Florack, Hendrik Jan Bosch
  • Patent number: 8445444
    Abstract: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: May 21, 2013
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Patent number: 8410252
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: April 2, 2013
    Assignee: Immunex Corporation
    Inventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage
  • Patent number: 8372954
    Abstract: Phage display libraries are taught in which the recombinant phage population displays a plurality of potential binding fragments having preferred characteristics of solubility and/or intermolecular interaction. Also taught are methods of biasing display libraries to produce variants which more closely approximate the preferred characteristics of the parental binding fragment.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: February 12, 2013
    Assignee: National Research Council of Canada
    Inventors: Jamshid Tanha, Joycelyn Entwistle, Saran Narang, Michael Dan, Colin R. Mackenzie, Carole Grad
  • Patent number: 8372798
    Abstract: Provided is a pharmaceutical composition involving a concentrated mixture of a precipitated protein and a liquid medium and a method for manufacturing the concentrated mixture. The concentrated mixture is manufacturable by precipitation of a protein with a biocompatible polymer precipitating agent, followed by removal of sufficient liquid to concentrate the resulting mixture to the desired degree. The precipitated protein can be stored for a significant time in the concentrated mixture, such as intermediate between processing stages during manufacture operations.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: February 12, 2013
    Assignee: Endo Pharmaceuticals Colorado, Inc.
    Inventors: John F. Carpenter, Jeffrey B. Etter, Adrian C. Samaniego
  • Publication number: 20130029428
    Abstract: A method of preparing an antigen-immobilized immuno-fluorescence slide, the method comprising: immobilizing a C-reactive protein on a slide to prepare a protein chip; mixing an antibody that specifically binds to a target protein, with streptavidin to label the antibody with a fluorescent nanoparticle; immuno-reacting the antibody by competitive mixing, assaying with a fluorescence camera, wherein the immobilizing of the C-reactive protein on the slide comprises: modifying the slide with 3-aminopropyltrimethoxysilane to prepare a modified slide; hydrating the slide modified with 3-aminopropyltrimethoxysilane; activating the modified slide by using a glutaraldehyde solution; dissolving a C-reactive protein at a concentration of 0.01-0.5 mg/ml in a 30-70 mM phosphate buffer solution (pH 6.5-7.
    Type: Application
    Filed: February 21, 2011
    Publication date: January 31, 2013
    Applicant: KOREA FOOD RESEARCH INSTITUTE
    Inventors: Nam Soo Kim, Yong Jin Cho, Chong Tai Kim
  • Publication number: 20120329176
    Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 27, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
  • Publication number: 20120329127
    Abstract: The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.
    Type: Application
    Filed: May 25, 2012
    Publication date: December 27, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Juergen Siekmann, Alfred Weber, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 8329875
    Abstract: Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2. Such monoclonal antibodies are of prognostic and diagnostic utility in the investigation of cancer, particularly metastatic cancer. The antibodies described may also be used in prognosis or diagnosis of inflammatory diseases. Also provided are kits and solid supports comprising such antibodies, as well as the therapeutic use of antibodies of the invention.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 11, 2012
    Assignee: The University Of Liverpool
    Inventors: Roger Barraclough, Dong Liu Barraclough, Philip Rudland
  • Publication number: 20120295287
    Abstract: This document provides methods and materials related to detecting neurotransmitters and other biologically active small molecules. For example, methods for detecting and measuring hapten levels in a biological sample using antibodies specific for conjugated haptens are provided.
    Type: Application
    Filed: November 8, 2010
    Publication date: November 22, 2012
    Applicant: Pharmasan Labs, Inc.
    Inventors: Gottfried H. Kellermann, Han J.G. Huisman
  • Patent number: 8309306
    Abstract: The invention provides methods, kits, devices and compositions for detecting one or more target analytes. In some embodiments, the invention provides binding elements and labeling elements capable of being joined through a plurality of joining elements.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: November 13, 2012
    Assignee: Nodality, Inc.
    Inventors: Garry Nolan, Philip McGarrigle
  • Publication number: 20120283408
    Abstract: A fusion protein that includes a polypeptide binding specifically to a constant region of an antibody and a stabilization protein linked to a terminus of the polypeptide, a polynucleotide encoding the fusion protein, a cell including the polynucleotide, a method of preparing the fusion protein, and a method of isolating an antibody by using the fusion protein.
    Type: Application
    Filed: August 6, 2010
    Publication date: November 8, 2012
    Applicant: SAMSUNG ELECTRONIC CO., LTD.
    Inventors: Jae-Il Lee, Young-Sun Lee, Tae-Soo Lee
  • Patent number: 8299220
    Abstract: This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein. Provided too, are the IRTA proteins encoded by the isolated nucleic acid molecules, IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins, having the amino acid sequences set forth in any of FIG. 18A, 18B-1-18B-3, 18C-1-18C-2, 18D-1-18D-2 or 18E-1-18E-2. Oligonucleotides of the isolated nucleic acid molecules are provided. Antibodies directed to an epitope of a purified IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins are also provided, as are pharmaceutical compositions comprising such antibodies or oligonucleotides. Methods for detecting a B cell malignancy in a sample from a subject; diagnosing B cell malignancy in a sample from a subject; detecting human IRTA protein in a sample; and treating a subject having a B cell cancer are also provided.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: October 30, 2012
    Assignee: Trustees of Columbia University in the City of New York
    Inventor: Riccardo Dalla-Favera
  • Publication number: 20120258115
    Abstract: A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.
    Type: Application
    Filed: April 11, 2012
    Publication date: October 11, 2012
    Inventor: Elizabeth SHANAHAN-PRENDERGAST
  • Publication number: 20120258077
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: June 14, 2012
    Publication date: October 11, 2012
    Applicant: Theraclone Sciences, Inc.
    Inventors: Matthew Moyle, Jennifer Mitcham
  • Publication number: 20120208294
    Abstract: The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.
    Type: Application
    Filed: July 16, 2010
    Publication date: August 16, 2012
    Applicant: RANDOX LABORATORIES LTD.
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Ivan Robert Mcconnell
  • Publication number: 20120123096
    Abstract: Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3? conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3? A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3? conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3? conjugate.
    Type: Application
    Filed: March 2, 2010
    Publication date: May 17, 2012
    Inventors: John G. Bruno, Judson C. Miner
  • Publication number: 20120115244
    Abstract: Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by an immunoassay (IA) employing an acridinium (Acr)-labeled anti-neopterin Ab as conjugate, and (iv) neopterin by an IA employing Acr-labeled neopterin as tracer; an Acr-labeled anti-neopterin Ab; a conjugate/complex comprising anti-neopterin Ab and a carrier scaffold; a conjugated pterin; a conjugate comprising an Acr-labeled pterin and a carrier scaffold; an immunogen comprising neopterin and a carrier protein; a conjugate comprising such an immunogen and an Acr compound; an immunogen comprising a carrier protein and a neopterin hapten; a conjugate comprising such an immunogen and an Acr compound; a kit for assaying a pterin comprising a pterin as a capture agent and instructions for IA; and a kit for assaying neopterin comprising an anti-neopterin Ab as a capture agent and ins
    Type: Application
    Filed: November 9, 2010
    Publication date: May 10, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Maciej Adamczyk, R. Jeffrey Brashear, Stephen C. Hsu, Phillip G. Mattingly
  • Patent number: 8173398
    Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: May 8, 2012
    Assignee: Femta Pharmaceuticals, Inc.
    Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
  • Publication number: 20120107829
    Abstract: The present invention relates to the use of a composition comprising (a) at least three different amino acids, (b) at least two different amino acids and a saponin or (c) at least one dipeptide or tripeptide for stabilizing biomolecules immobilized on a solid carrier. The invention furthermore relates to a method for producing stabilized biomolecules, comprising embedding the biomolecules in the composition according to the invention and a method of producing a solid carrier having biomolecules attached thereto. The invention furthermore relates to a solid carrier producible or produced by the method of the invention and a method of diagnosing a disease using the carrier of the invention.
    Type: Application
    Filed: March 31, 2010
    Publication date: May 3, 2012
    Applicant: LEUKOCARE AG
    Inventors: Stefan Margraf, Anja Breuer, Martin Scholz, Jens Altrichter
  • Publication number: 20120094316
    Abstract: The invention relates to an immunoassay method and kit for the detection and/or the determination of mephedrone, mephedrone metabolites and related compounds. The invention is underpinned by a novel antibody, derived from a novel immunogen, that is sensitive and binds to mephedrone, mephedrone metabolites and related compounds.
    Type: Application
    Filed: October 18, 2011
    Publication date: April 19, 2012
    Inventors: Robert Ivan McConnell, Elouard Benchikh, Philip Andrew Lowry, Stephen Peter Fitzgerald
  • Patent number: 8129333
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: March 6, 2012
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 8129145
    Abstract: An improved system for large scale production of glycoproteins in cell culture is provided. In accordance with the present invention, cells expressing a glycoprotein are grown in media that contain manganese at a concentration of between approximately 10 and 600 nM. The use of such a system allows production of a glycoprotein with an increased glycosylation pattern and/or a glycosylation pattern that more accurately reflects the glycosylation pattern of the naturally occurring glycoprotein. A glycoprotein expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: March 6, 2012
    Assignee: Wyeth LLC
    Inventors: Daniel R. Lasko, Stephan M. Koza
  • Publication number: 20120040378
    Abstract: Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.
    Type: Application
    Filed: August 9, 2011
    Publication date: February 16, 2012
    Applicant: RANDOX LABORATORIES LIMITED
    Inventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
  • Patent number: 8110540
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: February 7, 2012
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 8110541
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: February 7, 2012
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 8105596
    Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: January 31, 2012
    Assignee: Immunomedics, Inc.
    Inventor: David M. Goldenberg
  • Publication number: 20120021437
    Abstract: Tetranor-PGDM/tetranor-PGJM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses in assay kits for detecting and quantifying tetranor-PGDM and tetranor-PGJM in biological fluids for determining biosynthesis of PGD2 in a subject or patient.
    Type: Application
    Filed: June 14, 2011
    Publication date: January 26, 2012
    Applicant: Cayman Chemical Company, Incorporated
    Inventors: Jeffrey K. Johnson, Kirk M. Maxey, Daniel J. Tew, Andriy M. Kornilov
  • Publication number: 20120003674
    Abstract: The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure.
    Type: Application
    Filed: June 29, 2011
    Publication date: January 5, 2012
    Applicant: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
  • Publication number: 20110318381
    Abstract: The structural design, preparative methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemisuccinyl-EDC-TFCS-tetanus toxoid and 3-O-carboxymethylmorphine-EDC-TFCS-tetanus toxoid), are disclosed. These vaccines are suitable for human use in which they are capable of triggering the synthesis of polyclonal antibodies against morphine opiate and its structural analogue, heroin, through the repeated in vivo administration of these formulations, in active vaccination protocols, in pre-clinical studies in rodents. The active vaccination paradigm through which these immunogens trigger a humoral immune response consolidated with a long-term immunological memory, characterized by the presence of high titers of specific antibodies against these two drugs of abuse, is also disclosed.
    Type: Application
    Filed: July 14, 2011
    Publication date: December 29, 2011
    Applicant: Instituto Nacional De Psiquiatria Ramon De La Fuente Muniz
    Inventors: Benito Anton PALMA, Philippe Leff GELMAN